Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial.

BACKGROUND Neurogenic bladder affects up to 80% of patients with multiple sclerosis (MS) and, in 50% of these patients, it is a significant cause of disability. The current management of neurogenic bladder, based on fluid restriction, anticholinergic agents, intermittent self-catheterization, and, in some cases, surgical intervention, often fails to relieve… CONTINUE READING